Vivasure’s PerQseal Elite Vascular Closure System Receives CE Mark Approval

April 22, 2025—Vivasure Medical, an Ireland-based developer of fully absorbable technology for percutaneous vessel closure, announced European CE Mark approval of the PerQseal Elite vascular closure system. The company stated it plans to launch PerQseal Elite in select European markets in Summer 2025.

According to the company, the PerQseal Elite is a sutureless and fully bioresorbable large-bore vessel closure device designed for closure after percutaneous cardiovascular procedures such as transcatheter aortic valve replacement and endovascular aortic repair.

Mohamed Abdel-Wahab, MD, Professor of Interventional Cardiology and Head of Structural Heart Disease Department at the Heart Center in Leipzig, Germany, discussed PerQseal Elite’s approval in the Vivasure announcement.

“Vascular closure remains a challenge for the growing cardiovascular procedures that require large-bore access,” commented Dr. Abdel-Wahab. “The introduction of PerQseal Elite is an exciting advancement for large-bore cardiovascular procedures. Having a fully absorbable, sutureless closure option simplifies the procedure and has the potential to reduce complications associated with traditional closure methods. We look forward to utilizing this technology to treat our patients.”

Vivasure’s PerQseal and PerQseal Elite are not available for sale in the United States, advised the company.